MorningSignal
Research Platform
2026-09-28 13:40
type: earnings-brief date: 2026-07-27 session: AM status: provisional tags: [earnings, sellside, morning] source_context: /Users/max/morningsignal-research/state/earnings/earnings_context_2026-07-27_AM.json
[[Daily/2026-07-27|Daily note]] · Deterministic evidence captured 2026-07-27 08:01:27 EDT
The morning is better operationally than the headline mix suggests, but it is not a broad “chase the beats” setup. AstraZeneca delivered a 5.2% core-EPS beat on essentially in-line revenue and retained its full-year growth framework; the quality is real, but the core/reported bridge is large and the unchanged guide does not clear a more demanding valuation-implied bar. Vodafone’s 5.2% organic service-revenue growth and 6.2% EBITDAaL growth show continued repair, led by Africa and Business, while the guidance increase is almost entirely the mechanical inclusion of nine months of Safaricom. Bank of Hawaii’s tiny EPS beat is less important than the ninth consecutive quarter of NIM expansion and 34.6% year-over-year PPNR growth, though the stock already discounts much of that repair. Alliance Resource Partners missed published EPS/revenue consensus, but adjusted EBITDA beat the dated independent hurdle and distribution coverage improved materially; the debate is now coal-price erosion versus contract coverage and disciplined leverage.
The only clean action is patience. AZN: HOLD, pending call evidence and a better entry against a roughly $170 weighted value. VOD: HOLD, because the operational repair is credible but the premarket move already carries the ADR to the base case. BOH: WAIT at or below $76, where the valuation would approach 2.0x current tangible book. ARLP: HOLD, collecting the distribution while testing cost and coverage thresholds. KOF: DEFERRED, because the issuer’s current Q2 release was not public at the 08:00 EDT cutoff. No prior-evening AMC company above $2 billion was found in the deterministic 2026-07-24 PM catch-up collection.
Premarket prices are indications, not settled closes: AZN $171.65 (+1.4% versus $169.26), VOD $15.86 (+4.7% versus $15.15), KOF $104.77 (+2.0% versus $102.71), BOH $86.49 (+3.0% versus $83.97), and ARLP $24.89 (+0.7% versus $24.71). The price moves were observed between 07:14 and 08:04 EDT and should not be interpreted as closing-market validation.
| Ticker | Tier | Release state at cutoff | Transcript/Q&A | Decision | Required length | Objective prose count | Gate |
|---|---|---|---|---|---|---|---|
| AZN | 1 | Current issuer release | Unavailable; PROVISIONAL | HOLD | ≥700 | 1,136 | Release gate pass; call gate pending |
| VOD | 1 | Current issuer presentation | Full Q&A unavailable; PROVISIONAL | HOLD | ≥700 | 1,048 | Release gate pass; call gate pending |
| BOH | 2 | Current issuer release | Call scheduled 14:00 EDT; PROVISIONAL | WAIT ≤$76 | ≥450 | 833 | Release gate pass; call gate pending |
| ARLP | 2 | Current issuer release | Call scheduled 10:00 EDT; PROVISIONAL | HOLD | ≥450 | 1,038 | Release gate pass; call gate pending |
| KOF | 3 | Current Q2 release absent at 08:00 EDT | Call scheduled 11:00 EDT | DEFERRED | 150–300 | 199 | Release gate failed; PM catch-up required |
“Objective prose count” excludes tables, headings, YAML, and source lists and is measured from the company section through its sources. Counts are reported for auditability and are rechecked after the file is written.
Decision: HOLD. Confidence: medium. Status: PROVISIONAL until full call/Q&A evidence is available. The print supports the long-duration oncology and rare-disease growth engine, but it does not create enough upside at the observed $171.65 ADR to override valuation, the unusually large core-to-reported bridge, and recent mixed late-stage pipeline outcomes. The best characterization is a good earnings result against a fair-to-demanding bar, not a thesis-changing beat.
| Item | Dated pre-print expectation / hurdle | Actual | Variance | Quality |
|---|---|---|---|---|
| Q2 core EPS | Nasdaq calendar $2.50, 2 estimates, captured 08:01 EDT | $2.63 | +$0.13 / +5.2% | Good operating beat, but see core bridge |
| Q2 revenue | Yahoo consensus $15.417B; range $15.185B–$15.700B, 15 analysts | $15.384B | -$33M / -0.2% | Essentially in line and inside range |
| FY26 revenue growth | Prior guide: mid-to-high single digit at CER | Reconfirmed | No change | Clears minimum hurdle; no raise |
| FY26 core EPS growth | Prior guide: low double digit at CER | Reconfirmed | No change | Clears minimum hurdle; no raise |
| TIF threshold | No formal company Ledger threshold found | N/A | N/A | Prior cross-work was technical, not a portfolio thesis |
The valuation-implied hurdle was higher than the published EPS number. At the observed $171.65 and an independently collected FY27 EPS mean of $8.77, the ADR trades at roughly 19.6x forward earnings. That multiple requires durable double-digit earnings growth, continued mid-teens oncology growth, and an absence of material pipeline-value destruction. The release cleared the near-term earnings hurdle, but unchanged guidance leaves little room to absorb a weaker product cycle or another late-stage miss.
Second-quarter total revenue rose 6% reported and 5% at constant exchange rates to $15.384 billion. Oncology was the main engine at $7.327 billion, up 16% reported and 15% CER. Respiratory and Immunology contributed $2.431 billion, up 13% reported and 11% CER. Cardiovascular, Renal and Metabolism fell 15% reported and 18% CER to $2.772 billion as Farxiga faced loss-of-exclusivity and China volume-based procurement pressure. The mix therefore matters: the consolidated growth rate understates oncology strength but also reveals an increasingly visible patent-and-price drag in CVRM.
Geographically, the United States grew 6% to $6.686 billion, emerging markets excluding China grew 14% reported and 11% CER to $2.334 billion, Europe grew 11% reported and 7% CER to $3.417 billion, and China declined 7% reported and 13% CER to $1.587 billion. China is the clearest negative rate-of-change item. It is not large enough to break the group guide today, but another two quarters of low-double-digit contraction would narrow the cushion carried by oncology and rare disease.
Product evidence remains broadly constructive. Tagrisso grew 7% reported and 6% CER in Q2 to $1.941 billion, while Imfinzi grew 27% in both measures to $1.854 billion. On a first-half basis, Ultomiris grew 16% reported and 14% CER to $2.584 billion, and Strensiq grew 41% reported and 40% CER to $1.053 billion. Those growth rates demonstrate that the portfolio is not dependent on one franchise. Conversely, Farxiga’s first-half U.S. decline of 17% and China/emerging-market decline of 13% CER show why the portfolio must keep replacing mature cash flows.
Core EPS rose 21% reported and 18% CER to $2.63, more than three times revenue growth. The operating leverage is genuine, but the reconciliation is essential. Reported operating profit was $3.164 billion, compared with core operating profit of $5.158 billion. The bridge included $100 million of restructuring, $1.546 billion of intangible amortization and impairments, and $348 million of other core adjustments. Reported EPS was $1.61; restructuring added $0.05, intangible items $0.79, and other adjustments $0.18 to arrive at core EPS. Intangible amortization is recurring for an acquisitive biopharma model, and Q2 R&D included a $345 million intangible impairment. The beat is high quality at the revenue and core operating line, but lower quality if one treats every “core” adjustment as economically irrelevant.
Sequentially, Q2 revenue was about 0.6% above the implied Q1 level of $15.288 billion, while core EPS increased about 1.9% from $2.58. That is steady rather than accelerating. The release also disclosed six positive Phase III readouts, but Wainua in CARDIO-TTRansform, Ultomiris in TMA-313, and Datroway in EMERALD-2 did not meet their primary endpoints. NILE was positive, and management still expects more than 20 Phase III readouts over the next 18 months. The pipeline offers upside but also explains why a simple earnings multiple understates event risk.
Management reconfirmed mid-to-high-single-digit 2026 revenue growth and low-double-digit core-EPS growth at CER, with a core tax rate of 18%–22%. If June 2026 exchange rates persist, foreign exchange should add a low-single-digit percentage to revenue growth, with EPS growth broadly similar. No guidance increase accompanied the 5.2% EPS beat.
Our release-only bridge starts from published FY26 EPS expectations around $7.64 and FY27 around $8.77. A modestly stronger core margin offsets the Q2 revenue shortfall, leaving a provisional FY26 range of $7.65–$7.85. For FY27, retain $8.60–$9.00 until management quantifies the Farxiga erosion curve, China pricing, and launch/readout cadence. The business delta is positive, the estimate delta is only modestly positive, and the stock delta is neutral-to-negative after the premarket move because the valuation already embeds the core growth.
| Scenario | Key operating assumptions | Value |
|---|---|---|
| Bear, 25% | Oncology slows below 10% CER, China remains down double digits, pipeline attrition raises the risk discount | $150 |
| Base, 50% | FY26 guide delivered; oncology stays low-to-mid teens; FY27 EPS near $8.8 at ~19x | $170 |
| Bull, 25% | Multiple positive readouts, >15% oncology growth and margin upside support ~22x $8.9 EPS | $195 |
| Weighted | 25% / 50% / 25% | $171 |
| Thesis pillar | Prior state | New evidence | State now |
|---|---|---|---|
| Oncology sustains the group growth engine | Constructive | Q2 oncology +15% CER; Imfinzi +27% | Strengthened |
| Rare disease diversifies growth | Constructive | Ultomiris +14% CER H1; Strensiq +40% CER | Strengthened |
| Mature-product erosion remains manageable | Unresolved | Farxiga U.S. -17%; China and EM -13% CER | Weakened |
| Pipeline replaces mature cash flows | High potential, high variance | Six positive Phase III studies, three named misses | Mixed |
| Valuation offers attractive asymmetry | Weak | Premarket price roughly equals weighted value | Unchanged / weak |
The prior TIF cross-work was the 2026-07-20 Pharmaceuticals, Biotechnology & Life Sciences InvestorDebate, where AZN ranked 22nd with a 6.19 average score. Fundamental work was favorable, but the technical specialist’s paper signal was SELL near $168.90 because three-month and year-to-date price confirmation was poor. That document was not a formal portfolio thesis or Ledger entry. Today’s earnings strengthen the fundamental side of that debate but do not falsify the technical concern: the observed reaction only takes the ADR modestly above that reference level.
Old narrative: a diversified oncology/rare-disease compounder whose earnings quality and pipeline breadth are offset by poor price confirmation and mature-product erosion. New narrative: the growth engine is operating better than the headline 5% CER revenue rate, but the margin-led EPS beat and unchanged guide do not yet create valuation upside; pipeline breadth remains an asset with visible binary costs.
The strongest bear argument is that the market is capitalizing adjusted earnings while economically recurring amortization, impairments, and R&D failures are relegated below “core.” The strongest bull rebuttal is that product-level revenue and core operating profit are cash-generative, oncology and rare disease have multiple independent growth nodes, and more than 20 near-term Phase III readouts create positive optionality. The release does not settle that debate. It modestly raises confidence in the operating engine and leaves the required return dependent on entry price.
Full prepared remarks and Q&A were not available by the 08:00 EDT workflow cutoff, so speaker-tone, analyst-question, language-delta, and evasion scoring are not available. Q&A exchanges reviewed: 0. Quantified language changes: 0. Unresolved omissions: 3.
Confirmation conditions: FY26 CER revenue growth of at least 7%, core-EPS growth of at least 10%, oncology growth remaining at or above 12% CER, and evidence that China contraction is stabilizing. Falsification conditions: a cut to either FY26 growth guide, oncology below 10% CER for two quarters, China deterioration beyond the low teens without an offset, or another cluster of high-value pipeline failures. Position action: HOLD; do not add above the $171 weighted value before call evidence. Revisit on a pullback below $155–$160 or on a demonstrable upward revision to FY27 EPS above $9.00.
Decision: HOLD. Confidence: medium. Status: PROVISIONAL until full call/Q&A evidence is available. The quarter confirms that Vodafone’s operating repair has moved beyond pure cost cutting: group organic service revenue increased 5.2% and adjusted EBITDAaL rose 6.2% on a like-for-like basis. The key limitation is expectations. The updated FY27 EBITDAaL range is a consolidation bridge for Safaricom, not a clean organic upgrade, and the observed $15.86 ADR already approximates the base-case value.
| Item | Dated expectation / prior guide | Actual / new guide | Interpretation |
|---|---|---|---|
| Q1 organic service revenue | Q4 FY26 growth was 5.1% | +5.2% | Small acceleration |
| Q1 adjusted EBITDAaL | No reliable quarterly Street range found | €3.0B; +6.2% LFL | Operating leverage above revenue |
| FY27 EBITDAaL | Company consensus mean €13.115B, range €12.621B–€13.580B; prior ex-Safaricom guide €11.9B–€12.2B | €13.0B–€13.3B including nine months of Safaricom | New midpoint €13.15B equals consensus; mechanical scope change |
| FY27 adjusted FCF | Consensus mean €2.780B, range €2.677B–€2.909B | Unchanged €2.6B–€2.9B | No cash-flow upgrade |
| FY27 adjusted EPS | Consensus 10.12 euro cents, range 7.79–12.79, 10 analysts | No quarterly EPS supplied | Pending |
| TIF threshold | No formal company Ledger threshold found | N/A | No catalyst test |
The published consensus is unusually useful because it came from Vodafone’s June 2026 company-collected analyst sheet. The new EBITDAaL midpoint of €13.15 billion is almost exactly the €13.115 billion mean, and management’s comment that it expects to land near the upper end is constructive but not yet a formal raise. Free-cash-flow guidance is unchanged despite including Safaricom, making cash conversion the principal hurdle. At $15.86 and a collected forward ADR EPS estimate of roughly $1.60, the stock trades near 9.9x forward earnings. That is not expensive, but a leveraged telecom merits a discount until integration, capital intensity, and deleveraging are visible in cash.
Group organic service-revenue growth of 5.2% was 10 basis points above Q4 FY26, while adjusted EBITDAaL growth of 6.2% exceeded revenue growth by roughly 100 basis points. EBITDAaL was €3.0 billion and the margin reached 28.5%, up 60 basis points like for like. That combination indicates real operating leverage rather than a revenue-only beat.
The geographic mix is more complicated. Germany, the crucial repair market, grew service revenue 1.2% after 0.9% in Q4. The improvement is directionally important because Germany was the central source of prior downgrades. It remains fragile: consumer mobile and business disconnections were still present, broadband net additions were negative, and the company continues to use commercial and network actions to rebuild customer quality. Incoming customer ARPU was reportedly about 30% above the outgoing base and cable NPS reached a company high, which supports the proposition that lower-volume acquisition can still improve future economics.
The United Kingdom grew service revenue 0.6%, down from 1.2% in Q4. Management frames the market as having momentum after the Three combination, but the reported rate of change decelerated. This is the main contradiction to test on the call: whether integration benefits, price actions, and network gains are being offset by accounting comparability or whether the commercial trajectory actually softened. Africa/Vodacom accelerated to 12.6% growth from 10.9%, while Business improved to 5.0% from 4.0%. Digital Services grew 18.8% and represented 28% of Business revenue. Those businesses provide genuine diversification away from mature European connectivity.
Safaricom closed on June 30. Vodafone lifted the FY27 adjusted EBITDAaL range from €11.9B–€12.2B excluding Safaricom to €13.0B–€13.3B including nine months of consolidation, an increment of €1.1 billion at both ends. Because the range width and implied legacy midpoint are unchanged, this is almost entirely a scope bridge. It is strategically useful—Safaricom adds structurally faster growth—but it is not evidence that the legacy business exceeded the prior full-year plan.
Cost actions also deserve a balanced reading. Reports referenced approximately 1,200 European role reductions as the company pursues roughly £700 million of annual cost and capital-spending savings by FY30. Cost removal can sustain margins, but indiscriminate cuts can undermine customer service or network execution. The 60-basis-point margin improvement is evidence of near-term benefit; German churn, NPS, and network quality must confirm that the savings do not borrow from future retention.
The release supports the existing FY27 EBITDAaL consensus rather than forcing a large revision. Set our provisional FY27 range at €13.1B–€13.3B, centered toward the upper half of guidance, versus the Street mean of €13.115B. Retain adjusted free cash flow at €2.75B–€2.90B until Safaricom minority leakage, integration cash costs, spectrum, and working capital are reconciled. For FY28, a 3%–5% organic service-revenue growth rate, modest margin expansion, and a full year of Safaricom imply EBITDAaL of approximately €13.8B–€14.4B; that is a scenario range, not management guidance.
The business delta is positive: Germany improved, Africa accelerated, Business strengthened, and EBITDA grew faster than revenue. The estimate delta is only slightly positive because the company’s updated midpoint matches consensus and free-cash-flow guidance did not rise. The stock delta is neutral after a 4.7% premarket indication because much of the incremental confidence is immediately capitalized.
| ADR scenario | Assumptions | Multiple / value |
|---|---|---|
| Bear, 25% | Germany stalls, UK integration drags, FCF below €2.6B | 8x ~$1.60 = $12.80 |
| Base, 50% | Guide delivered, modest European repair, leverage normalizes | 10x ~$1.60 = $16.00 |
| Bull, 25% | Germany and UK both >2%; Safaricom expands mix and cash flow | 12x ~$1.60 = $19.20 |
| Weighted | 25% / 50% / 25% | $16.00 |
| Thesis pillar | Prior state | New evidence | State now |
|---|---|---|---|
| Germany can return to sustainable growth | Unproven | Service revenue +1.2% vs +0.9%; customer counts still weak | Modestly strengthened |
| UK combination creates profitable momentum | Constructive | Service growth +0.6% vs +1.2% in Q4 | Mixed / weakened |
| Growth mix improves through Africa and Business | Constructive | Africa +12.6%; Business +5.0%; Digital Services +18.8% | Strengthened |
| Cost program expands margins without hurting service | Unproven | Margin +60 bps; 1,200 role reductions reported | Strengthened near term, still a watch item |
| Cash conversion and leverage validate equity value | Unresolved | FCF guide unchanged; Safaricom newly consolidated | Unchanged |
Old narrative: a low-multiple European telecom restructuring whose value depends on Germany stabilization and UK integration. New narrative: the restructuring is producing measurable group growth and margin expansion, with Africa and digital services reducing dependence on Europe, but the formal guidance increase is acquisition accounting and the decisive free-cash-flow proof is still absent.
The strongest bear case is that service-revenue growth is flattered by high-inflation African markets while mature Europe remains low growth, capital intensive, and competitive. Safaricom adds minority and currency complexity, and job cuts can conceal underinvestment. The strongest bull case is that Germany has crossed back into growth, the UK network combination creates scale economics, Business digital mix is compounding, and a sub-10x forward multiple requires only steady delivery rather than perfection. The evidence shifts the debate toward the bull on operations but not enough on cash.
Full call Q&A was unavailable at the cutoff. Speaker-level tone, analyst pushback, language changes, and evasion scores are not available. Q&A exchanges reviewed: 0. Quantified language changes: 0. Unresolved omissions: 4.
Confirmation conditions: Germany service revenue stays above 1% and reaches 2%; UK returns above 1%; FY27 EBITDAaL is at least €13.2 billion; adjusted FCF is at least €2.8 billion; leverage returns to the lower half of the 2.25x–2.75x policy range. Falsification conditions: Germany turns negative again, UK synergies slip materially, FY27 FCF falls below €2.6 billion, or leverage remains above 2.75x without a credible asset or cash bridge. Position action: HOLD and do not chase the premarket indication. A more attractive entry is below $14.50 absent an earnings upgrade; add only after call evidence substantiates cash conversion.
Decision: WAIT at or below $76. Confidence: medium. Status: PROVISIONAL; the 14:00 EDT call had not occurred. The core banking engine improved more than the $0.01 headline EPS beat implies: NIM expanded for a ninth consecutive quarter, PPNR grew 34.6% year over year, and expenses normalized. At the observed $86.49, however, the shares trade near 2.28x current tangible book and roughly 12.6x FY27 consensus EPS. That valuation leaves inadequate room for deposit pressure or credit normalization.
| Metric | Pre-print | Q2 actual | Variance |
|---|---|---|---|
| EPS | $1.4608 mean; $1.42–$1.52 range, 7 analysts | $1.47 | +$0.009 / +0.6% |
| Total revenue | $199.452M mean; $198.0M–$202.108M range, 5 analysts | $196.903M | -$2.549M / -1.3% |
| FY26 EPS | $6.008 mean, 7 analysts | No annual EPS guide | Pending bridge |
| FY27 EPS | $6.874 mean, 7 analysts | No annual EPS guide | Pending bridge |
| TIF threshold | No formal company Ledger threshold found | N/A | No catalyst test |
The EPS beat was only about $0.4 million after tax. Q2 expenses included a $0.5 million benefit from stock-award forfeitures, while Q1 included $3.5 million of accelerated vesting and $0.7 million of separation costs. The current benefit alone was larger than 30% of the approximate dollar value of the beat, so the headline beat is low quality at the margin. That does not undermine the underlying result: PPNR, NIM, and normalized expenses all improved materially.
Net interest income was $153.604 million, up 1.7% sequentially and 18.4% year over year. NIM expanded four basis points quarter over quarter and 39 basis points year over year to 2.78%, the ninth consecutive quarterly increase. Total deposit cost rose only one basis point to 1.27%, and the reported downward beta was 35.5%. The asset repricing and funding discipline are working, though the release did not provide a forward NIM range.
Loans were $14.287 billion, up 0.7% sequentially and 2.0% year over year; average loans rose 1.0% sequentially. Deposits were $20.893 billion, down 0.3% sequentially but up 0.5% year over year; average deposits fell 0.4% sequentially. Noninterest-bearing deposits were 26.7% of the base versus 27.2% in December. Loan growth without corresponding average-deposit growth can eventually pressure funding costs, so the modest quarter-end stability is not enough to dismiss the mix risk.
Fee income was $43.299 million, up 4.8% sequentially but down 3.3% year over year; on the company’s adjusted presentation it rose 5.3% sequentially. Expenses fell 4.2% sequentially to $111.186 million and increased just 0.4% year over year. The efficiency ratio improved to 56.47% from 60.35% in Q1 and 63.49% a year ago. PPNR rose 12.4% sequentially and 34.6% year over year to $85.717 million. The efficiency improvement, not the one-cent EPS beat, is the durable positive.
Credit remains benign but no longer pristine. Provision expense was $3.6 million versus $1.75 million in Q1. Net charge-offs increased to $3.4 million, or 10 basis points annualized, from $1.1 million, or 3 basis points. Nonperforming assets improved one basis point to 0.08%, and the allowance declined one basis point to 1.03% of loans. A 10-basis-point charge-off rate is not concerning; the rate of change simply means that extrapolating zero-loss conditions would be imprudent.
Tangible book value reached $38.01 per share, up from $37.31 in Q1 and $34.37 a year ago. CET1 improved to 12.12% from 12.06%. BOH repurchased 216,000 shares for $17 million at an average $78.70 and retained $88.9 million of authorization. Repurchasing below the current market price but above 2x tangible book is defensible only if the earnings repair is durable. Capital is strong enough to support it, but the valuation makes buyback accretion modest.
Starting from FY26 consensus EPS of $6.01, the Q2 result and NIM trajectory support a provisional $6.05–$6.15 range. For FY27, the published mean of $6.87 remains reasonable; our range is $6.85–$7.10 if NIM stays at or above 2.75%, credit costs remain below 20 basis points, and expenses grow no faster than low single digits. Revenue consensus is $808.5 million for FY26 and $870.4 million for FY27. The Q2 revenue miss creates a small near-term negative, but margin and expense quality offset it in the EPS bridge.
The business delta is positive, the estimate delta is slightly positive, and the stock delta is negative after a 3% premarket indication because the market price already assumes continued NIM repair. A tangible-book valuation is more informative than a headline P/E for this balance-sheet-sensitive bank.
| Scenario | Assumptions | Value |
|---|---|---|
| Bear, 25% | NIM slips below 2.70%; charge-offs >20 bps; deposits contract | $70 |
| Base, 50% | NIM 2.75%–2.85%; FY27 EPS ~$6.9; TBV compounds | $82 |
| Bull, 25% | NIM >2.90%; clean credit; FY27 EPS >$7.1 | $96 |
| Weighted | 25% / 50% / 25% | $82.50 |
| Pillar | Evidence | Change |
|---|---|---|
| Margin repair | Ninth consecutive NIM increase; +39 bps YoY | Strengthened |
| Deposit franchise | Costs controlled, but average balances and noninterest mix declined | Mixed |
| Operating efficiency | PPNR +34.6% YoY; efficiency ratio 56.47% | Strengthened |
| Credit normalization | NCOs 10 bps vs 3 bps; NPAs only 0.08% | Slightly weakened, still healthy |
| Valuation asymmetry | 2.28x current TBV at indicated price | Weakened |
Old narrative: a premium island deposit franchise awaiting margin normalization. New narrative: the margin and PPNR normalization are visibly underway, but the market has already capitalized much of the repair and the next debate shifts to deposit durability and credit costs. The bull case is a scarce, high-quality franchise with excess capital and multiple quarters of repricing tailwind. The bear case is that a 2.3x tangible-book valuation capitalizes peak NIM improvement before deposit beta and credit losses fully normalize.
Call evidence is unavailable. Q&A exchanges reviewed: 0. Language changes quantified: 0. Unresolved omissions: 3. Ask management to (1) provide a quarterly NIM path and quantify remaining fixed-rate asset repricing; (2) explain the divergence between loan growth and average-deposit contraction, including the cost of incremental funding; and (3) quantify criticized/classified loan migration behind the rise in charge-offs. Confirmation: NIM at least 2.80%, deposits stable to positive, NCOs below 15 basis points, and efficiency below 58%. Falsification: NIM below 2.70%, quarterly deposits down more than 2%, or NCOs above 20 basis points. Action: wait for $76 or less, approximately 2.0x current TBV; do not chase the initial reaction.
Decision: HOLD. Confidence: medium. Status: PROVISIONAL; the 10:00 EDT call had not occurred. The result is operationally better than the EPS miss implies. Revenue was slightly below the published range and EPU missed both the Nasdaq and broader public-data means, yet adjusted EBITDA exceeded the dated independent hurdle, distribution coverage recovered to 1.39x, and leverage remains below 1.0x despite the AllDale acquisition. The offset is continued realized coal-price erosion and higher Illinois Basin unit costs.
| Metric | Pre-print stack | Q2 actual | Variance |
|---|---|---|---|
| Revenue | Yahoo mean $556.0M, range $553.5M–$557.4M, 3 analysts | $551.6M | -$4.4M / -0.8% vs mean; below range |
| EPU | Yahoo mean $0.653, range $0.62–$0.68; Nasdaq $0.62, 2 estimates | $0.61 | -$0.043 / -6.6% vs mean; -$0.01 / -1.6% vs Nasdaq |
| Adjusted EBITDA | Channelchek 2026-07-14 hurdle $181.2M | $185.7M | +$4.5M / +2.5% |
| Distribution | $0.60 quarterly / $2.40 annualized | $0.60; coverage 1.39x | Maintained; coverage +39% QoQ |
| TIF threshold | No formal company Ledger threshold found | N/A | No catalyst test |
The consensus set is thin and internally dispersed, so the exact hurdle must remain visible. The Channelchek preview expected $553.5 million of revenue, $181.2 million of adjusted EBITDA, and $0.62 EPU; its full-year view was $2.209 billion of revenue, $723.7 million of EBITDA, and $2.22 EPS. Against that dated stack, revenue and EPU missed narrowly while EBITDA beat. That is a better-quality operating result than a screen based only on EPS would indicate.
Revenue rose 0.7% year over year and 6.9% sequentially to $551.6 million. Adjusted EBITDA rose 14.7% year over year and 19.8% sequentially to $185.7 million. Coal sales volume reached 8.558 million tons, up 2.1% year over year and 8.9% sequentially. The group realized coal price declined 5.3% year over year and 2.7% sequentially to $54.87 per ton. Volume, mix, and non-coal earnings more than offset price pressure at EBITDA, but the declining realization is the central risk.
Illinois Basin volume was 6.367 million tons, down 4.5% year over year but up 4.9% sequentially. Price per ton increased 0.5% year over year and 1.6% sequentially to $51.87, while segment expense per ton rose 3.7% year over year and 2.2% sequentially to $35.99. Segment EBITDA declined 8.8% year over year but improved 5.1% sequentially to $104.2 million. The cost rate remains acceptable inside company guidance, but year-over-year price/cost spread compression is visible.
Appalachian volume rose 27.6% year over year and 22.3% sequentially to 2.191 million tons. Price per ton fell 22.9% year over year and 14.7% sequentially to $63.57, but expense per ton fell even faster—29.7% year over year and 25.7% sequentially—to $46.22. Segment EBITDA increased 67.2% year over year and 87.9% sequentially to $49.2 million. This is the best evidence of operating adaptation: lower price did not prevent substantial profit growth because volume and unit costs improved.
Oil and gas royalty revenue rose 30.5% year over year to $46.3 million, and segment EBITDA reached $38.0 million versus $29.9 million a year ago and $34.6 million in Q1. Production volumes increased 6.4% year over year but declined 8.4% sequentially due to natural well decline. The royalties diversify cash generation, though production without continued operator drilling naturally decays.
Net income was $79.6 million, or $0.61 per unit, compared with $59.4 million, or $0.46, a year ago. The year-over-year comparison benefited from prior-period impairment effects and current equity-method/investment changes. ARLP also held 646 bitcoin acquired for $37.9 million. These factors can create volatility below EBITDA. The EPS miss is therefore less informative than the simultaneous EBITDA beat and cash-distribution coverage.
Distributable cash flow was $108.2 million and coverage was 1.39x, up roughly 39% sequentially. Total debt was $590.2 million, cash was $111.2 million, total leverage was 0.82x, and net leverage was 0.67x. Liquidity was approximately $424 million. The balance sheet retains substantial cushion even after the $206.2 million AllDale acquisition, financed with cash, revolver borrowings, and a new $150 million term loan.
AllDale adds roughly 48,500 acres and expands the royalty portfolio. The company also added 21.2 million contracted coal tons. It now reports 34.3 million tons committed for 2026—effectively covering the midpoint of the 33.75–35.25 million ton sales guide—and 29.4 million tons for 2027. Contract coverage materially reduces volume risk; it does not fully eliminate price resets, counterparty behavior, force majeure, or inflation in mining costs.
Management retained 2026 coal sales guidance of 33.75–35.25 million tons, total coal price of $54–$56 per ton, and expense of $37–$39 per ton. Oil guidance is 1.95–2.05 million barrels, gas 10.0–10.5 Bcf, and NGL 1.1–1.2 million barrels. G&A is expected at $95–$100 million, interest expense at $49–$52 million, and capital spending at $280–$300 million.
The release supports a provisional FY26 revenue range of $2.20B–$2.23B and adjusted EBITDA of $725M–$745M, modestly above Channelchek’s $723.7 million hurdle at the midpoint. FY26 EPU is more uncertain because investment, tax, and non-operating items matter; use $2.25–$2.40 rather than the public-data mean of $2.38 as a point estimate. For FY27, public consensus is roughly $2.31 billion of revenue and $2.89 EPU. Our provisional range is $2.30B–$2.35B of revenue, $760M–$800M of EBITDA, and $2.75–$3.00 EPU if contracted tonnage converts and unit cost stays below $39.
At $24.89, the annualized $2.40 distribution yields about 9.6%. Public market data indicated approximately 5.5x EV/EBITDA and 8.6x FY27 EPS. The high cash yield compensates for commodity and partnership-tax complexity, but does not make the security riskless.
| Scenario | Assumptions | Value |
|---|---|---|
| Bear, 25% | Realization < $52/ton, cost >$39, coverage <1.1x | $20 |
| Base, 50% | Guidance midpoint, coverage ≥1.3x, leverage <1.0x | $25 |
| Bull, 25% | Appalachia mix persists, royalties grow, EBITDA >$800M | $30 |
| Weighted | 25% / 50% / 25% | $25 |
| Pillar | Evidence | Change |
|---|---|---|
| Contract book protects volume | 34.3M tons committed for 2026; 29.4M for 2027 | Strengthened |
| Unit economics withstand lower price | Group price -5.3% YoY; Appalachia EBITDA +67.2% | Strengthened, mix-dependent |
| Distribution is covered | 1.39x coverage; DCF $108.2M | Strengthened |
| Balance sheet remains conservative | Net leverage 0.67x after acquisition | Strengthened |
| Coal-price durability | Realization -5.3% YoY and -2.7% QoQ | Weakened |
Old narrative: a high-yield coal partnership whose contract coverage and low leverage buffer secular and commodity risk. New narrative: the buffer is working—volume, cost execution, royalties, and coverage offset lower prices—but the EBITDA resilience must repeat before the market should treat the 9.6% yield as fully secure. The bull case is contracted volume plus rare low leverage and a diversified royalty stream. The bear case is that today’s EBITDA strength reflects favorable mix while realized prices continue to fall, capex remains heavy, and the AllDale purchase raises fixed financing needs.
No call Q&A was available at the cutoff. Exchanges reviewed: 0. Language changes: 0. Unresolved omissions: 4. Ask management to (1) bridge the 21.2 million newly contracted tons by year, basin, price mechanism, and counterparty; (2) quantify expected AllDale EBITDA, maintenance needs, and distribution accretion after financing; (3) explain why group coal realization should remain inside $54–$56 after two sequential declines; and (4) state the distribution policy if coverage falls below 1.2x.
Confirmation: Q3 volume at least 8.8 million tons, total coal cost at or below $38 per ton, distribution coverage at or above 1.3x, and leverage at or below 1.0x after acquisition closing. Falsification: realized price below $52 with cost above $39, coverage below 1.1x, leverage above 1.25x, or loss of material contracted tonnage. Action: HOLD; do not add solely for yield before the call. Add only below $23 or after two quarters of ≥1.3x coverage with net leverage ≤1.0x.
Decision: DEFERRED. Tier 3. Status: BLOCKED at the 08:00 EDT cutoff. Coca-Cola FEMSA’s investor-relations page still identified 1Q26 as its latest report, while the issuer’s calendar invitation confirmed that Q2 results were scheduled for release before the market on July 27 and that the conference call would begin at 11:00 EDT. The collector’s apparent “actual” revenue of MXN70.926 billion is stale Q1 data and is denominated in pesos; comparing it with a dollar-denominated Q2 consensus would be a category error. It is excluded.
The pre-print stack is retained for the PM catch-up: Nasdaq EPS consensus $1.65 from one estimate; broader public-data quarterly EPS mean approximately $1.542 with a $1.433–$1.65 range from two analysts; quarterly revenue mean $4.350 billion with a $4.304B–$4.414B range from nine analysts. FY26 revenue consensus was approximately $17.58 billion and FY27 $18.89 billion. At the observed $104.77 ADR, public data indicated roughly 12.8x forward earnings and a 4.1% dividend yield. Those figures define the bar but are not evidence of a print.
Exact required input: the issuer’s Q2 2026 earnings release, financial statements, and full call transcript/Q&A. Deadline: PM EarningsBrief catch-up at 20:00 EDT on 2026-07-27. No position action is authorized before the release is verified.
| Ticker | Business delta | FY1/FY2 estimate delta | Stock delta at observed premarket price | Net thesis change |
|---|---|---|---|---|
| AZN | Positive: oncology and rare disease strong; China/Farxiga weak | Slightly positive / unchanged pending call | Neutral-negative; price ≈ weighted value | Fundamental pillar stronger, valuation unchanged |
| VOD | Positive: Germany/Africa/Business and margin improve; UK decelerates | Slightly positive FY27; FCF unchanged | Neutral-negative after +4.7% indication | Repair more credible, cash proof pending |
| BOH | Positive: NIM/PPNR/efficiency | Slightly positive FY26/FY27 | Negative at 2.28x TBV | Earnings repair confirmed, asymmetry worse |
| ARLP | Positive at EBITDA/coverage; negative realized coal price | FY26 EBITDA slightly positive; EPU mixed | Neutral near $25 value | Yield coverage stronger, price risk unresolved |
| KOF | Unknown | Unknown | Unusable before release | Deferred |
morningsignal-am.FREQ=WEEKLY;BYDAY=MO,TU,WE,TH,FR;BYHOUR=8;BYMINUTE=0./Users/max/morningsignal-research/collect_earnings_context.py --date 2026-07-27 --session AM.2026-07-24 --session PM found zero qualifying companies above $2 billion.